Free press releases distribution network?

Agency / Source: VentureWeb Design Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



NeuroMedix Poised to Realize Next Stage of Business Plan through Strategic Alliance or Acquisition - Neuromedix has made important progress in the cure of Alzheimer's disease, and is planning for the next phase of product development through strategic alliance or acquisition - NeuroMedixInc.com
NeuroMedix Poised to Realize Next Stage of Business Plan through Strategic Alliance or Acquisition

 

PRZOOM - /newswire/ - Toronto, Ontario, Canada, 2006/11/29 - Neuromedix has made important progress in the cure of Alzheimer's disease, and is planning for the next phase of product development through strategic alliance or acquisition - NeuroMedixInc.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

NeuroMedix Inc. (“NeuroMedix” or the “Company”) (TSXV: NMX) today announced that based on the positive pre-clinical development data received to date for its lead product, Minozac, it will now explore licensing or acquisition transactions with a view to maximizing shareholder value.

“As we complete the final stages of our pre-clinical development program and prepare towards the submission of our Phase I safety application to the regulatory authorities, our Board of Directors has directed management to seek strategic alliances with pharmaceutical and biotechnology partners and to explore merger and acquisition transactions”, said Dr. Mark L. Pearson, Chief Executive Officer, “Consistent with our business strategy, we plan to seek partners or acquirers with the financial resources to further advance the clinical development of Minozac in a bid to ensure Minozac’s rapid development to benefit patients with Alzheimer’s and other neuroinflammatory brain indications. Our Board has assessed Minozac’s commercial potential in several large markets, including the treatment of Alzheimer’s disease, and believes this path will maximize value to NeuroMedix shareholders.”

As a first step in this business strategy, NeuroMedix plans to complete an interim financing before the end of the year.

NeuroMedix provides no assurance that the implementation of a process to explore licensing or acquisition transactions with a view to maximizing shareholder value will result in a transaction. No decision has been made to enter into any transaction at this time. The Company will retain investment bankers to provide financial advice to NeuroMedix in this process.

About NeuroMedix

NeuroMedix (neuromedixinc.com) is a biotechnology company focused on the development of therapeutic agents for the treatment of degenerative and inflammatory diseases of the central nervous system, such as Alzheimer’s disease, traumatic brain injury, neuropathic pain, age-related macular degeneration and multiple sclerosis. Our therapeutic drug candidates are based on research from a team of leading experts in the field of neuroinflammation at Northwestern University and have been demonstrated to reduce brain inflammation, to protect neuronal cells, and to prevent the loss of cognitive function in an Alzheimer’s disease animal model in mice. Our lead candidate, Minozac has also been shown to reduce inflammation and prevent loss of cognitive function in mice suffering traumatic brain injury. Based on these findings, NeuroMedix is pursuing the development of its lead compound for Alzheimer’s disease and traumatic brain injury in humans. NeuroMedix’s shares are listed on the TSX Venture Exchange under the symbol “NMX”.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: VentureWeb Design Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


NeuroMedix Poised to Realize Next Stage of Business Plan through Strategic Alliance or Acquisition

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Mark Pearson, PhD - NeuroMedixInc.com 
425-503-5156 mark[.]neuromedixinc.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any VentureWeb Design Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From VentureWeb Design Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0
MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  MagLar, Inc.

Visit  BizJobs.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today